Moreover, steady-state intracellular pH (pHi) and the capacity for net acid extrusion are elevated in human breast cancer tissue compared to normal breast tissue. (A) Exemplar fluorescence images of …
Data file containing NBCn1 and NHE1 protein expression levels, steady-state intracellular pH (pHi) values, and net acid extrusion capacities linked to de-identified clinical and pathological patient characteristics.
Note that this source data file pertains to Figure 1 but it also contains the clinicopathological information used for stratification in Figures 2–5, 7, and 8, and Figure 2—figure supplement 1; for the multiple linear and logistic regression analyses in Figure 6; and for the plots in Figure 6—figure supplement 1.
(A) Primary breast cancer tissue (n=75–76). (B) Normal breast tissue (n=48–49). Figure 1—figure supplement 1—source data 1 provides the data pertaining to this figure and used for stratification in …
Data file containing net acid extrusion capacities calculated at specified intracellular pH (pHi) levels and linked to de-identified clinical and pathological patient characteristics.
Note that this source data file pertains to Figure 1—figure supplement 1 but it also contains the clinicopathological information used for stratification in Figure 2—figure supplements 1 and 2, Figure 3—figure supplement 1, Figure 4—figure supplement 1, Figure 5—figure supplement 1, Figure 7—figure supplement 1, and Figure 8—figure supplement 1.
(A,B) Traces of NH4+-prepulse-induced pHi dynamics in human invasive lobular (A, n=8–9) and ductal (B, n=60–62) breast carcinomas. The time scale within the dotted rectangles is expanded in order to …
(A) Traces of NH4+-prepulse-induced pHi dynamics in human mucinous adenocarcinomas (n=5). The time scale within the dotted rectangle is expanded in order to improve resolution during the pHi …
(A) Invasive lobular primary breast carcinomas (n=8–9). (B) Invasive ductal primary breast carcinomas (n=60–62).
(A–C) Traces of NH4+-prepulse-induced pHi dynamics in human invasive ductal breast carcinomas of malignancy grades I (A, n=12–14), II (B, n=34), and III (C, n=14). The time scale within the dotted …
(A) Primary breast carcinomas of malignancy grade I (n=12–14). (B) Primary breast carcinomas of malignancy grade II (n=34). (C) Primary breast carcinomas of malignancy grade III (n=14).
(A,B) Traces of NH4+-prepulse-induced pHi dynamics in human breast carcinomas stratified by estrogen receptor status (A: negative, n=6; B: positive, n=63–64). The time scale within the dotted …
(A) Estrogen receptor-negative primary breast carcinomas (n=6). (B) Estrogen receptor-positive primary breast carcinomas (n=63–64).
(A,B) Traces of NH4+-prepulse-induced intracellular pH (pHi) dynamics in human HER2-positive (A, n=9–11) and HER2-normal (B, n=58–61) breast carcinomas. The time scale within the dotted rectangles …
(A) HER2-positive primary breast carcinomas (n=9–11). (B) HER2-normal primary breast carcinomas (n=58–61).
(A–D) Multiple linear regression analyses show the independent influences of patient age, tumor size, histology, malignancy grade, and expression of estrogen and HER2 receptors on steady-state pHi …
Statistical relationships among the variables were tested by Spearman’s correlation analyses.
(A,B) Traces of NH4+-prepulse-induced pHi dynamics in breast carcinomas with high (A, 35–90% Ki67+, n=19–20) and low (B, 0–30% Ki67+, n=49–51) Ki67 index. The time scale within the dotted rectangles …
(A) Primary breast carcinomas with high proliferative index (35–90% Ki67+ cells; n=19–20). (B) Primary breast carcinomas with low proliferative index (0–30% Ki67+ cells; n=49–51).
(A,B) Traces of NH4+-prepulse-induced intracellular pH (pHi) dynamics in primary breast carcinomas from patients with (A, n=25–28) and without (B, n=42–44) axillary lymph node metastases. Time …
(A) Primary breast carcinomas from patients with lymph node metastases (n=25–28). (B) Primary breast carcinomas from patients with no lymph node metastases (n=42–44).
(A) Variation in SLC9A1 mRNA levels among patients with different breast cancer subtypes (n=135–344). Expression data were compared by one-way ANOVA followed by Tukey’s post-test. Figure 9—figure …
The mRNA expression for SLC9A1 correlates with that of ESR1 and ERBB2.
When adjusted for expression of ESR1, PGR, and ERBB2, the mRNA expression of SLC9A1 does not correlate with that of SLC4A7, SLC16A1, and SLC16A3 (n=409–1162).
We observe systematic differences in mRNA levels for estrogen (A: ESR1, n=135–344), progesterone (B: PGR, n=162–438), and HER2 (C: ERBB2, n=162–438) receptors, the proliferative marker Ki67 (D: MKI67…
(A) Variation in SLC4A7 mRNA levels among patients with different breast cancer subtypes (n=135–344). Expression data were compared by one-way ANOVA followed by Tukey’s post-test. *p<0.05, ***p<0.001…
The mRNA expression for SLC4A7 correlates with that of ESR1, PGR, and ERBB2.
When adjusted for expression of ESR1, PGR, and ERBB2, the mRNA expression of SLC4A7 does not correlate with that of SLC9A1, SLC16A1, and SLC16A3 (n=409–1162).
(A) Variation in SLC16A1 mRNA levels among patients with different breast cancer subtypes (n=162–438). Expression data were compared by one-way ANOVA followed by Tukey’s post-test. Figure 10—figure …
The mRNA expression for SLC16A1 correlates with that of ESR1, PGR, and ERBB2.
When adjusted for expression of ESR1, PGR, and ERBB2, the mRNA expression of SLC16A1 does not correlate with that of SLC4A7, SLC9A1, and SLC16A3 (n=409–1457).
(A) Variation in SLC16A3 mRNA levels among patients with different breast cancer subtypes (24–141). Expression data were compared by one-way ANOVA followed by Tukey’s post-test. Figure 10—figure …
The mRNA expression for SLC16A3 correlates with that of ESR1, PGR, and ERBB2.
When adjusted for expression of ESR1, PGR, and ERBB2, the mRNA expression of SLC16A3 does not correlate with that of SLC4A7, SLC9A1, and SLC16A1 (n=409).
The image was generated with BioRender.com.
Number of patients | 110 |
Patient age (years; median, interquartile range) | 64.5 (56–74) |
Tumor size (mm; median, interquartile range) | 18 (14–26) |
Histological type | |
Invasive ductal carcinomas | 92 (84%) |
Invasive lobular carcinomas | 92 (84%) |
Mucinous adenocarcinomas | 5 (5%) |
Tubular carcinoma | 2 (2%) |
Pleomorphic lobular carcinoma | 1 (1%) |
HER2 receptor status | |
Normal | 95 (86%) |
Overexpression or gene amplification | 15 (14%) |
Estrogen receptor status | |
90–100% ER+ cells | 99 (90%) |
0–15% ER+ cells | 11 (10%) |
Malignancy grade | |
I | 31 (28%) |
II | 52 (47%) |
III | 22 (20%) |
Not graded | 5 (5%) |
Axillary lymph node status | |
Negative | 69 (63%) |
Isolated tumor cells | 15 (14%) |
Micro-metastases | 5 (5%) |
Macro-metastases | 21 (19%) |
Ki67 index | |
0–30% Ki67+ cells | 82 (75%) |
35–90% Ki67+ cells | 28 (25%) |
Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
---|---|---|---|---|
Gene (Homo sapiens) | SLC4A7 | GenBank | Gene ID: 9497 | Encodes NBCn1 |
Gene (Homo sapiens) | SLC9A1 | GenBank | Gene ID: 6548 | Encodes NHE1 |
Gene (Homo sapiens) | SLC16A1 | GenBank | Gene ID: 6566 | Encodes MCT1 |
Gene (Homo sapiens) | SLC16A3 | GenBank | Gene ID: 9123 | Encodes MCT4 |
Biological sample (Homo sapiens) | Surgical breast biopsies | Regionshospitalet Randers, Denmark | This study cohort | Cancer and matched normal tissue |
Chemical compound, drug | Collagenase type 3 | Worthington Biochemical Corporation | Cat. #: LS004182 | 450 IU/mL |
Chemical compound, drug | BCECF-AM | Thermo Fisher Scientific | Cat. #: B1170 | 3 µM |
Antibody | Anti-NBCn1 (Rabbit polyclonal) | Jeppe Praetorius, Aarhus University, Denmark Damkier et al., 2006 | Reference | IHC (1:100) |
Antibody | Anti-NHE1 (Mouse monoclonal) | Santa Cruz Biotechnology | Cat. #: sc-136239; RRID:AB_2191254 | IHC (1:100) |
Commercial assay, kit | OptiView DAB IHC detection kit | Roche Diagnostics | RRID:AB_2833075 | Goat anti-rabbit and anti-mouse |
Software, algorithm | SPSS | IBM | RRID:SCR_002865 | |
Software, algorithm | Prism | GraphPad | RRID:SCR_002798 | Version 9.1.1 |